Index

Note: Page numbers of article titles are in boldface type.

A
Alternate reading frame protein (ARFP) defined, 85 implications for design of novel anti-HCV strategies, 85 Amantadine/PEG-IFN/ribavirin for nonresponders to chronic HCV management, 126–127 Amdoxovir for HBV infection, 75 Antiviral agents for naive patients with HCV infection, 99–113. See also Hepatitis C virus (HCV) infection, naive patients with, treatment of, antiviral therapy in Antiviral therapy preemptive for recurrent HCV infection in liver transplant patients, 164–167 ARFP. See Alternate reading frame protein (ARFP)

C
Chemoembolization transarterial for HCC, 15–16 Chemotherapy systemic for HCC, 16–17 CIFN. See Consensus interferon (CIFN) Cis-acting elements implications for design of novel anti-HCV strategies, 93 Clevudine for HBV infection, 74 Consensus interferon (CIFN)/ribavirin for nonresponders to chronic HCV management, 125–126

E
E1/E2 implications for design of novel anti-HCV strategies, 85–86 Emtricitabine for HBV infection, 72–74

G
Genotype(s) HBV role of, 68–70

H
HAPs. See Heteroaryldihydropyrimidines (HAPs) HCC. See Hepatocellular carcinoma (HCC) HCV infection. See Hepatitis C virus (HCV) infection Hepatitis. See also under Hepatitis C virus (HCV) infection; specific type, e.g., Hepatitis B virus (HBV) infection types of, 1–2 Hepatitis B virus (HBV), 47–61 described, 47–50 DNA assays of clinical applications of, 54–55 detection and quantification of molecular techniques for, 55–60 Hepatitis B virus (HBV) core antigen isolated antibody to screening for before HBV immunization, 30–31 Hepatitis B virus (HBV) genotypes role of, 68–70
Hepatitis B virus (HBV) infection
  acute, 51–53
  chronic, 53–54, 63–79
  assessment of, 66–67
  monitoring of, 66–67
  natural history of, 63–66
  prevalence of, 63
  progression to, 50–51
  treatment of
    amdoxovir in, 75
    clevudine in, 74
    emtricitabine in, 72–74
    goals in, 71–72
    HAPs in, 75
    lobucavir in, 75
    new agents in, 72–74
    β-L-nucleosides in, 74
    patient selection for, 67–68
    pradefovir in, 75
    telbivudine in, 74
    tenofovir in, 72
  HCC and, 1–25. See also
    Hepatocellular carcinoma (HCC)
  molecular virology of
    antiviral implications of, 83–92
    novel antiviral strategies, 81–98
    ARFP, 85
    cis-acting elements, 93
    core protein, 85
    E1/E2, 85–86
    host targets, 91–92
    NS2, 86
    NS3, 86–87
    NS4A, 87–88
    NS4B, 88–89
    NS5A, 90
    NS5B, 90–91
    p7, 86
  naive patients with
    treatment of
      antiviral therapy in, 99–113
      adherence to, 108–109
      adverse effects of, 110–111
      benefits of, 111
      combination therapy of
        interferon with
        ribavirin, 102–103
      cost effectiveness of, 111
      early virological response
to, 106–108
      historical perspective of,
      101–102
      patient selection for,
      100–101
      PEGIFN monotherapy,
      103–105
      PEGIFN/ribavirin
      therapy, 105–106
      pretreatment predictors of
      response to, 106
    recurrence of
      in liver transplant patients
      management of, 155–174
      interferons in, 161–162
      preemptive antiviral
      therapy in, 164–167

Hepatitis C virus (HCV) infection
  chronic
    combination therapy for
      relapse after
      future directions in,
      148–149
      mechanisms of, 138–139
      prediction of sustained
      virologic response to,
      144–145
      rates of, 137–138
      treatment of, 137–153. See also
      specific agents,
      e.g., Interferon/ribavirin
    fibrosis progression in
  modifying lifestyle factors
    associated with, 129–130
  management of
    failure of
      reasons for, 116–124
      in patients who failed to
      achieve sustained
      virologic response
      therapies under
      investigation, 124–127
      maintenance, 127–129
      interferon in, 127–128
      ribavirin in, 128–129
  HCC and, 1–25. See also
    Hepatocellular carcinoma (HCC)
  molecular virology of
    antiviral implications of, 83–92
    novel antiviral strategies, 81–98

Hepatocellular carcinoma (HCC)
  molecular diagnosis of, 54–60
  prevalence of, 27
  serologic diagnosis of, 51–54
  vaccines for, 27–45
  adverse effects of, 39
  efficacy of, 35–38
  immunogenicity of, 31–33
  immunotherapy using, 39
  indications for, 27–30
  nonresponse to
    management of, 38–39
    predictors of, 34–35
    prevaccination screening in,
    30–31
    routes of administration of,
    33–34
    screening for isolated antibody to
    HBV core antigen in,
    30–31
  naive patients with
    treatment of
      antiviral therapy in, 99–113
      adherence to, 108–109
      adverse effects of, 110–111
      benefits of, 111
      combination therapy of
      interferon with
      ribavirin, 102–103
      cost effectiveness of, 111
      early virological response
to, 106–108
      historical perspective of,
      101–102
      patient selection for,
      100–101
      PEGIFN monotherapy,
      103–105
      PEGIFN/ribavirin
      therapy, 105–106
      pretreatment predictors of
      response to, 106
    recurrence of
      in liver transplant patients
      management of, 155–174
      interferons in, 161–162
      preemptive antiviral
      therapy in, 164–167
natural history of, 156–157
prevention of, 162–167
prevalence of, 155
retransplantation for, 167–170
severity of
factors associated with, 157–161

Hepatitis C virus (HCV) replicons, 92–94

Hepatocellular carcinoma (HCC), 1–25
clinical presentation of, 1–2
diagnosis of, 2–3
HBV–associated, 1–25
HCV–associated, 1–25
mortality due to, 27
prevention of, 6–8
screening for, 3–6, 70–71
treatment of, 8–20
introduction to, 8
liver transplantation in, 9–12
percutaneous ethanol injection in, 12–13
radiofrequency ablation in, 13–15
surgical resection in, 8–9
systemic chemotherapy in, 16–17
TACE in, 15–16

Heteroaryldihydropyrimidines (HAPs)
for HBV infection, 75

Host targets
implications for design of novel anti-
HCV strategies, 91–92

Interferon(s) (IFNs)/ribavirin
for retreatment of interferon
monotherapy relapers in chronic
HCV infection treatment, 140–144

Interferon(s) (IFNs)/ribavirin
for retreatment of interferon
monotherapy relapers in chronic
HCV infection treatment, 140–144

Life cycle
overview of, 81–83

Lifestyle modifications
fibrosis progression and, 129–130

Liver transplantation
for HCC, 9–12
recurrent HCV infection after
management of, 155–174. See also Hepatitis C virus (HCV) infection, recurrence of, in liver transplant patients, management of
natural history of, 156–157

Lobucavir
for HBV infection, 75

Molecular virology
of HCV infection
implications for novel therapies, 81–98. See also Hepatitis C virus (HCV) infection, molecular virology of, novel antiviral strategies

NS2
implications for design of novel anti-HCV strategies, 86

NS3
implications for design of novel anti-HCV strategies, 86–87

NS4A
implications for design of novel anti-HCV strategies, 87–88

NS4B
implications for design of novel anti-HCV strategies, 88–89

NS5A
implications for design of novel anti-HCV strategies, 90

NS5B
implications for design of novel anti-HCV strategies, 90–91
ß-L-Nucleoside(s)
for HBV infection, 74
implications for design of novel anti-HCV strategies, 86

PEGIFN. See Peginterferon (PEGIFN)

Peginterferon (PEGIFN) alfa
for naive patients with HCV infection, 103–105

Peginterferon (PEGIFN)/ribavirin
for chronic HCV infection
relapse after treatment of, 147–148
for naive patients with HCV infection, 105–106
higher doses and longer duration of for nonresponders to chronic HCV management, 126

Peginterferon (PEGIFN)/ribavirin/amantadine
for nonresponders to chronic HCV management, 126–127

Percutaneous ethanol injection
for HCC, 12–13

Pradefovir
for HBV infection, 75

Protease inhibitors
for nonresponders to chronic HCV management, 125

Protein(s)
core
implications for design of novel anti-HCV strategies, 85

Radiofrequency ablation
for HCC, 13–15

Ribavirin
in maintenance management of HCV infection in patients who failed to achieve sustained virologic response, 128–129
Ribavirin/CIFN
for nonresponders to chronic HCV management, 125–126
Ribavirin/IFN
for naive patients with HCV infection, 102–103
Ribavirin/PEGIFN
for naive patients with HCV infection, 105–106
for nonresponders to chronic HCV management, 126
Ribavirin/PEGIFN/amantadine
for nonresponders to chronic HCV management, 126–127

Systemic chemotherapy
for HCC, 16–17

TACE. See Transarterial chemoembolization (TACE)
Telbivudine
for HBV infection, 74
Tenofovir
for HBV infection, 72
Transarterial chemoembolization (TACE)
for HCC, 15–16
Transplantation liver. See Liver transplantation

HBV, 27–45. See also Hepatitis B virus (HBV) infection, vaccines for